T-cell receptor, or TCR, therapy is a cancer treatment that genetically reprograms immune cells, called T cells, to hunt down cancer with precision. It’s similar to another treatment, CAR T-cell therapy, but with one key difference: CAR T-cell therapy can only spot proteins that naturally appear outside a cancer cell. TCR therapy, however, can also catch small protein fragments from inside the cell that are carried to the surface and displayed like little name tags.

Many prostate cancers depend on androgen hormones, including testosterone, to grow. That is why treatments for advanced disease often try to reduce testosterone production or block its effects. Now, scientists have identified an unexpected participant in androgen chemistry: a bacterium from the human urinary tract that can convert the steroid precursor DHEA into testosterone under laboratory conditions.

CAR T-cell therapy is an immune-reprogramming procedure that turns a patient’s own immune cells into cancer-fighting specialists. The entire process is complex, but researchers have now found a faster way to achieve similar effects using a single intravenous (IV) drip of a harmless engineered virus.

Researchers from Harvard Medical School found that they can tweak a gene and turn a patient’s own pancreatic cells into insulin-producing cells.

New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow range of cancers, could potentially be more broadly applicable to a wide range of cancers when combined with immunotherapy.

Researchers at Johns Hopkins Medicine have uncovered a critical biological mechanism that helps explain how inflammation is triggered and sustained in a wide range of diseases—highlighting a promising avenue for future therapeutic development.

A lab-grown micro bladder may explain why urinary tract infections (UTIs) return so frequently, according to a study led by researchers at UCL, the University of Oxford and the University of Leicester.

Atherosclerosis predominantly affects regions of the arteries that bend or branch, creating disturbances in blood flow dynamics that activate cells’ inflammatory pathways and eventually lead to plaque buildup.

A Cleveland Clinic first-in-human clinical trial has shown that a one-time infusion of a gene-editing therapy using CRISPR-Cas9 was effective and safe in reducing LDL (“bad”) cholesterol and triglycerides in people with medication-resistant lipid disorders through one year of follow-up across all doses.